Open Access iconOpen Access

VIEWPOINT

crossmark

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma

ALESSANDRO GOZZETTI*, MONICA BOCCHIA

Division of Hematology, University of Siena, Azienda Ospedaliera Universitaria, Siena, 53100, Italy

* Corresponding Author: Alessandro Gozzetti, email

Oncology Research 2023, 31(3), 271-274. https://doi.org/10.32604/or.2023.028668

Abstract

Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival and has become widely used not-only in clinical trials but also in daily patient management. Bone marrow aspiration is the gold standard for response evaluation, but due to the patchy nature of myeloma, false negatives are possible. Liquid biopsy and blood-based minimal residual disease evaluation consider circulating plasma cells, mass spectrometry or circulating tumour DNA. This approach is less invasive, can provide a more comprehensive picture of the disease and could become the future of response evaluation in multiple myeloma patients.

Keywords


Cite This Article

GOZZETTI, A., BOCCHIA, M. (2023). Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma. Oncology Research, 31(3), 271–274.



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1004

    View

  • 544

    Download

  • 1

    Like

Share Link